Kent D Stewart

List of Publications by Year in Descending Order

93 papers	3,977 citations	37 h-index	61 g-index
96 ext. papers	4,192 ext. citations	4.9 avg, IF	4.05 L-index

#	Paper	IF	Citations
93	Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. *Journal of Medicinal Chemistry*, **2018**, 61, 1153-1163	8.3	13
92	Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4399-404	2.9	12
91	Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195. *ACS Medicinal Chemistry Letters*, **2013**, 4, 211-5	4.3	19
90	Design and synthesis of tricyclic cores for kinase inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 693-8	2.9	19
89	Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3487-90	2.9	6
88	Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3208-12	2.9	20
87	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7615-22	2.9	11
86	Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4750-5	2.9	12
85	Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4528-31	2.9	4
84	Contribution of indazolinone tautomers to kinase activity. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4502-5	2.9	1
83	The Drug Guru Project **2012**, 183-198		1
82	Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5620-4	2.9	40
81	Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1876-9	2.9	9
80	Cheminformatic tools for medicinal chemists. *Journal of Medicinal Chemistry*, **2010**, 53, 4830-41	8.3	63
79	Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 612-7	2.9	26
78	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2452-5	2.9	45
77	Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. *Journal of Medicinal Chemistry*, **2009**, 52, 6621-36	8.3	73

76	Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 3174-83	8.3	32
75	3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases. *Journal of Medicinal Chemistry*, **2008**, 51, 1231-41	8.3	29
74	Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 386-90	2.9	35
73	Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2691-5	2.9	28
72	Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3887-90	2.9	18
71	Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5206-8	2.9	52
70	7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. *Journal of Medicinal Chemistry*, **2008**, 51, 3777-87	8.3	44
69	Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-NЏ(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. *Journal of Medicinal Chemistry*, **2007**, 50, 1584-97	8.3	160
68	Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2759-67	3.4	33
67	Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2005-12	2.9	30
66	Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 3136-40	2.9	15
65	1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 3618-23	2.9	11
64	Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5665-70	2.9	5
63	Discovery of 4Ў(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4Ў(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2Ўcarbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5944-51	2.9	25
62	Thienopyridine urea inhibitors of KDR kinase. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1246-9	2.9	40
61	Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. *Antiviral Research*, **2007**, 76, 93-7	10.8	38
60	Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery. *Journal of Computer-Aided Molecular Design*, **2007**, 21, 121-30	4.2	6
59	Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 732-5	5.9	13

58	Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors. *Journal of Medicinal Chemistry*, **2007**, 50, 1983-7	8.3	71
57	Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. *Biochemistry*, **2007**, 46, 9551-63	3.2	89
56	Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. *Journal of Medicinal Chemistry*, **2007**, 50, 1514-27	8.3	68
55	Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. *Journal of Medicinal Chemistry*, **2007**, 50, 4162-76	8.3	35
54	Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 6226-30	2.9	17
53	Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 3520-35	8.3	54
52	Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors. *Biochemistry*, **2006**, 45, 7474-82	3.2	39
51	Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3-(trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of	8.3	47
50	Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. *Journal of Medicinal Chemistry*, **2006**, 49, 6416-20	8.3	37
49	Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4371-5	2.9	23
48	Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4326-30	2.9	21
47	1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4266-71	2.9	23
46	Drug Guru: a computer software program for drug design using medicinal chemistry rules. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 7011-22	3.4	86
45	Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 3980-90	8.3	54
44	An unusual intramolecular hetero-Diels-Alder cycloaddition. *Journal of Organic Chemistry*, **2005**, 70, 3332-5	4.2	3
43	Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 6066-83	8.3	142
42	Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core. *Bioorganic and Medicinal Chemistry Letters* , **2005**, 15, 125-8	2.9	25
41	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 93-8	2.9	17

40	Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. *Journal of Medicinal Chemistry*, **2005**, 48, 744-52	8.3	134
39	An intramolecular ionic hydrogen bond stabilizes a cis amide bond rotamer of a ring-opened rapamycin-degradation product. *Magnetic Resonance in Chemistry*, **2005**, 43, 41-6	2.1	8
38	Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 5499-503	2.9	20
37	Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. *Tumor Biology*, **2005**, 26, 71-80	2.9	22
36	Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 4305-14	5.9	117
35	Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 2260-6	5.9	155
34	Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. *Virology*, **2004**, 329, 319-27	3.6	38
33	Isoindolinone ureas: a novel class of KDR kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4505-9	2.9	27
32	Formation, isolation and characterization of an AB-biaryl atropisomer of oritavancin. *Tetrahedron*, **2004**, 60, 10611-10618	2.4	3
31	An "inside-the-box" approach to drug resistance. *Chemistry and Biology*, **2004**, 11, 1327-8		
30	Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3063-8	2.9	9
29	Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. *Journal of Medicinal Chemistry*, **2004**, 47, 303-24	8.3	65
28	Interaction with the S1 pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3063-3068	2.9	20
27	Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. *Antiviral Research*, **2003**, 59, 173-80	10.8	29
26	Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. *Biochemistry*, **2003**, 42, 718-27	3.2	104
25	Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 3425-9	2.9	18
24	X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 2803-6	3.4	88
23	In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. *Journal of Virology*, **2002**, 76, 5380-6	6.6	42

22	Synthesis of an influenza neuraminidase inhibitor intermediate via a highly diastereoselective coupling reaction. *Organic Letters*, **2002**, 4, 1427-30	6.2	21
21	Species specificity of amidine-based urokinase inhibitors. *Biochemistry*, **2001**, 40, 9125-31	3.2	24
20	Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. *Journal of Medicinal Chemistry*, **2001**, 44, 1192-201	8.3	124
19	Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. *Structure*, **2000**, 8, 553-63	5.2	51
18	The 2.2 A structure of the rRNA methyltransferase ErmCUand its complexes with cofactor and cofactor analogs: implications for the reaction mechanism. *Journal of Molecular Biology*, **1999**, 289, 277-91	6.5	85
17	Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 529-34	2.9	23
16	ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 3218-24	5.9	419
15	In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. *Journal of Virology*, **1998**, 72, 7532-41	6.6	128
14	Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 699-704	2.9	4
13	A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. *Journal of Medicinal Chemistry*, **1996**, 39, 392-7	8.3	60
12	Investigation into the diastereomeric composition of a pyruvamide dimer. *Journal of Heterocyclic Chemistry*, **1993**, 30, 1153-1154	1.9	1
11	Survey of the DNA binding properties of natural and synthetic polyamino compounds. *Journal of Physical Organic Chemistry*, **1992**, 5, 461-466	2.1	46
10	DOCKing ligands into receptors: The test case of Echymotrypsin. *Tetrahedron Computer Methodology*, **1990**, 3, 713-722		11
9	New shapes in HIV protease inhibitors. *Protein Engineering, Design and Selection*, **1990**, 4, 1-2	1.9	3
8	Computerized Probe Analysis of the Energetically Favored Binding Sites of an Aspartyl Protease. *Annals of the New York Academy of Sciences*, **1990**, 616, 611-612	6.5	
7	Designed DNA Interactions **1990**, 75-80		
6	Molecular basis for potentiation of bleomycin-mediated degradation of DNA by polyamines. Experimental and molecular mechanical studies. *Journal of Molecular Recognition*, **1989**, 2, 158-66	2.6	44
5	The effect of structural changes in a polyamine backbone on its DNA-binding properties. *Biochemical and Biophysical Research Communications*, **1988**, 152, 1441-6	3.4	44

4	Host-guest complexation. 42. Preorganization strongly enhances the tendancy of hemispherands to form hemispheraplexes. *Journal of the American Chemical Society*, **1987**, 109, 3098-3107	16.4	73
3	Host-guest complexation. 40. Synthesis and complexation of macrocyclic hosts containing cyclic ureas, anisyls, and steric barriers. *Journal of Organic Chemistry*, **1986**, 51, 4327-4337	4.2	8
2	The catalytic oxidation of dithiols by a semisynthetic enzyme. *Journal of the American Chemical Society*, **1986**, 108, 3480-3483	16.4	12
1	Complementary solutes enter nonpolar preorganized cavities in lipophilic noncomplementary media. *Journal of the American Chemical Society*, **1985**, 107, 2574-2575	16.4	57